Medical Product Research and Development

The Department of the Army Medical Command established this Master IDIQ on July 31, 2015, to procure medical product development services in support of the U.S. Army Medical Materiel Development Activity, U.S. Army Medical Materiel Agency, and subordinate commands within USAMRMC, with a shared ceiling of $900 million. Ordering closed on August 1, 2020—the vehicle is no longer active.

The vehicle has executed 29 task orders with a combined potential value of $66.5 million, of which $60.5 million (91 percent) has been obligated. Ordering activity peaked in 2016 with 12 awards, declining sharply thereafter to single digits annually and ceasing after August 2020. The vehicle funded clinical trials, market research, analyses of alternatives, and regulatory support across disease areas including HIV vaccines, dengue, chikungunya, tafenoquine, and hemorrhage control; work included phase 2B proof-of-concept studies, toxicity assessments, and FDA compliance training.

PPD Development LP leads by order count with 19 awards valued at $24.6 million combined, while Dynport Vaccine Company LLC holds the largest combined potential value at $26.5 million across three orders. Leidos, Inc. received 6 orders worth $10.1 million; Engility Services, LLC captured 1 order for $5.2 million. No small-business set-asides were used across the vehicle's entire portfolio—all 29 awards were unrestricted competitive.

The Department of the Army Medical Command placed 25 orders worth $26.9 million combined potential value; the Defense Health Agency placed 4 orders worth $39.6 million, indicating Defense Health Agency concentration in the vehicle's largest task orders. Notable mega-orders include tafenoquine clinical trials ($24.2 million), clinical monitoring for phase 2B HIV vaccine study ($11.6 million potential), and chikungunya vaccine evaluation ($5.2 million). Pricing was mixed, combining firm fixed price, cost plus fixed fee, and time and materials structures. The vehicle's extended ordering window and steep decline in annual activity after 2016 suggest customer funding constraints or consolidation of work onto successor vehicles.

This requirement is for all medical product development services required to support the U.S. Army Medical Materiel Development Activity (USAMMDA), the U.S. Army Medical Materiel Agency (USAMMA), other U.S. Army Medical Research and Materiel Command (USAMRMC) subordinate commands, and Chemical Biological Medical Systems (CBMS) in their missions to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation.